BNCT is a type of particle beam radiation therapy that utilizes an α particle and 7Li nucleus generated when a thermal neutron is captured by a 10B nucleus involved in the boron compound that has been taken up into tumor tissue selectively. In this report, the relevance of N/C ratio of tumor cell and anti-tumor effect for BNCT clinical cases of head and neck cancer were verified. Examination of pre-irradiated tumor histopathological specimens of 9 BNCT treated head and neck cancer patients (4 CR patients, 5 non-CR patients) was performed. The statistically significant difference between the CR group and the non-CR group was examined for the physical dose was multiplied by the absolute biological effectiveness (ABE) value determined from the patient's tumor specific N/C ratio. Analysis showed the mean tumor dose could not distinguish between CR and non-CR groups. However, the ABE dose could clearly distinguish between the CR group and the non-CR group (p = 0.0250). The N/C ratio of tumor cell can influence the anti-tumor effect of BNCT for HNC.

BNCT 是一种粒子束放射治疗，它利用 α 粒子和 7Li 核，当热中子被 10B 核俘获时，硼化合物被选择性地吸收到肿瘤组织中。本报告验证了肿瘤细胞N/C比值与抗肿瘤作用与BNCT临床头颈癌病例的相关性。对 9 名接受 BNCT 治疗的头颈癌患者（4 名 CR 患者，5 名非 CR 患者）的照射前肿瘤组织病理学标本进行了检查。检查 CR 组和非 CR 组之间的统计学显着差异，将物理剂量乘以根据患者肿瘤特异性 N/C 比确定的绝对生物有效性 (ABE) 值。分析显示平均肿瘤剂量无法区分 CR 组和非 CR 组。然而，ABE 剂量可以清楚地区分 CR 组和非 CR 组（p = 0.0250）。肿瘤细胞的N/C比值会影响BNCT对HNC的抗肿瘤作用。